Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival

Journal of Clinical Oncology

Volumn 27, Issue 25, 2009, Pages 4135-4141

  Fu, Pingfu ^a   Dowlati, Afshin ^a   Schluchter, Mark ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; MATHEMATICAL MODEL; METHODOLOGY; PANCREAS CARCINOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; BIOLOGICAL MODEL; CELL PROLIFERATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; EVALUATION; FEASIBILITY STUDY; HUMAN; NEOPLASM; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 70249148990     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.6709     Document Type: Article

References (21)

1. Goyeneche AA, Carón RW, Telleria CM: Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clinical Cancer Res 13:3370-3379, 2007
2. Fox E, Curt GA, Balis FM: Clinical trial design for targeted therapy. Oncologist 7:401-409, 2002
3. Karrison TG, Maitland ML, Stadler WM, et al: Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99:1455-1461, 2007
4. Ratain MJ, Eckhardt SG: Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 22:4442-4445, 2004
5. Booth CM, Calvert AH, Giaccone G, et al: Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 44:25-29, 2008
6. Shi H, Guo J, Duff DJ, et al: Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis 28:60-70, 2007
7. Wooster R, Weber BL: Breast and ovarian cancer. N Engl J Med 348:2339-2347, 2003
8. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
9. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
10. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol, 23:7199-7206, 2005
11. Temple RJ: Special study designs: Early escape, enrichment, studies in non-responders. Commun Statist-Theory Meth 23:499-531, 1994
12. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-4484, 2002
13. Freidlin B, Simon R: Evaluation of randomized discontinuation design. J Clin Oncol 23:5094-5098, 2005
14. Dent S, Zee B, Dancey J, et al: Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol 19: 785-791, 2001
15. RH El-Maraghi, EA Eisenhauer: Review of phase II: Trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III. J Clin Oncol 26:1346-1354, 2008
16. Ratain MJ, Humphrey RW, Gordon GB, et al: Recommended changes to oncology clinical trial design: Revolution or evolution? Eur J Cancer 44:8-11, 2008
17. Kopec JA, Abrahamowicz M Esdaile JM: Randomized discontinuation trials: Utility and efficiency. J Clin Epidemiol 46:959-971, 1993
18. Capra WB: Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints. Control Clin Trials 25:168-177, 2004
19. Jiang Y, Pjesivac-Grbovic J, Cantrell C, et al: A multiscale model for avascular tumor growth. Biophys J 89:3884-3894, 2005
20. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006
21. Leber PD, Davis CS: Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 19:178-187, 1997